According to the announcement, Simcere Pharma reported a total of 2.60 billion issued shares as of February 28, 2026, unchanged from the preceding month. The public float requirement of 15.45% remained in compliance. The company has an outstanding restricted share unit scheme with a potential issuance of 237.37 million shares, although no new shares were issued or transferred in February.
Additionally, the announcement shows that 10.85 million shares were repurchased on June 13, 2025, but have not yet been canceled. No further changes in share capital were recorded during the reporting period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments